Medicare Bonus Payments: CMS Plans To End Three, But Considers Seven New-Tech Add-On Payments For FY 2019

While the US Medicare agency is proposing to end hospital inpatient new-technology add-on payments for Edwards Lifesciences’ and LivaNova’s minimally surgical valves, and for WL Gore's endoprosthesis aneurysm device, it is evaluating possible bonus payments for 7 more devices beginning Oct. 1.

Medicare, Health Concept

The US Centers for Medicare and Medicaid Services said it plans to stop new technology add-on payments for two minimally invasive prosthetic aortic valves and an endoprosthesis device for peripheral aneurysms in its recently-released inpatient prospective payment system (IPPS) proposed rule. Meanwhile, the agency is considering whether to add the bonus payments for seven other devices, including a stroke-protection device for transcatheter aortic valve procedures, a nerve stimulator to treat sleep apnea patients, and a nanotechnology-based interbody device used to treat patients with degenerative disk disease, among others. But none of them appear to be a sure thing based on comments in the proposed rule.

The table below summarizes FY 2018 new-tech add-on payments CMS proposed to end as of Sept. 30.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Policy & Regulation

More from Medtech Insight

TRiCares Tricuspid Valve Replacement System Reduces Regurgitation In First-In-Human Study

 

TRiCares presented data from the first-in-human study for its tricuspid valve replacement system – Topaz – at EuroPCR 2025 on 22 May.

Swiss Medtechs Advised To Work On US Tariff Mitigation Strategies

 
• By 

The US’ 90-day suspension of higher “reciprocal tariffs” will expire on 9 July, raising fears that the 31% tariff rate on Swiss medtech and other goods exported to the US might make a comeback. While the tariff situation changes on an almost daily basis, medtechs should forearm for any eventually, say local business organizations.

Guardant Health Launches Germline Hereditary Cancer Test

 

Guardant Health introduces a new germline panel test to help guide cancer treatment, assess the risk of secondary cancers in patients and identify family members at risk of cancer.